FGF6 is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGF6 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

FGF6 is altered in 4.17% of squamous cell lung carcinoma patients [3].

FGF6 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF6 is altered in 1.94% of endometrial carcinoma patients [3].

FGF6 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF6 is altered in 1.32% of gastric carcinoma patients [3].

FGF6 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF6 is altered in 1.63% of malignant solid tumor patients [3].

FGF6 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF6 is altered in 1.55% of cancer patients [3].

FGF6 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains FGF6 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

FGF6 is altered in 1.98% of cholangiocarcinoma patients [3].

FGF6 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGF6 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGF6 is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].